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ABSTRACT
Multiple sclerosis (MS) is a demyelinating disease of the central nervous sys-
tem (CNS). Experimental autoimmune encephalomyelitis (EAE) induced in
rodents has served as an animal model for MS. However, no animal model
established so far represents all the facets of human MS. Thus, it is warranted
to develop new models that simulate MS more closely. 
EAE is mediated by autoimmune CD4+ T cells, which develop first in the
peripheral lymphoid organs and migrate into the CNS to cause an autoimmune
response. Meanwhile, regulatory T cells may also develop to contain the harm-
ful autoimmune response to the myelin antigens. The development of T cells
is controlled largely by the expression of different cytokines as well as of cel-
lular adhesion molecules (CAMs). Thus, for understanding the pathogenesis
of the demyelinating disease, it is important to study the immune parameters
in the peripheral lymphoid organs. 
The methodology for quantification of the expression of molecules involved
in the immune system at the mRNA level was established. Although the method
was developed in vitro with cultured splenic cells, this technique was utilized
throughout this study. 
Chronic relapsing EAE (CR-EAE) was established through a novel regimen.
In this new model, more mice survived the acute disease attack and the major-
ity of the surviving mice developed CR-EAE that resembled human MS closely.
The relapsing-remitting course of the disease in this model is thus useful for
the study of the pathogenesis of MS and for therapeutic approaches. 
The cellular mechanism underlying the development of CR-EAE was investi-
gated. Through splenectomy and adoptive cell transfer, it was observed that the
spleen as well as the memory cells harboured in it played a prominent role in
the development of CR-EAE. 
ABSTRACT
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The expression profiles of cytokines and CAMs in the lymph nodes (LNs)
and spleen were studied. It was found that a stronger expression of the cytokines
IL-2, IFN-γ, IL-10 and CAMs VCAM-1, LFA-1, CD44 in the spleen than in
the lymph nodes correlated with disease remission in CR-EAE. These results
indicated that a polarized expression of different immune molecule in the dif-
ferent peripheral lymphoid organs may determine the outcome of the disease
progression. 
The expression of a particularly interesting novel adhesion molecule, ICAM-
5, was studied. With several techniques, it was demonstrated that the antigen
presenting cells: dendritic cells (DCs), macrophages and a small percentage
of B cells expressed ICAM-5. Quantitative RT-PCR analysis showed that a
higher expression of ICAM-5 in the spleen than in the LNs was associated with
disease remission in CR-EAE. 
Taken together, these results showed that a new mouse model for MS could
be developed with a modified protocol. The study of various parameters in
the peripheral lymphoid organs indicated that the activities in the different
immune compartments may evolve differentially in remission and relapse.
Interactions between the subsets of immune cells which are developed in the
different compartments may determine the net outcome of the immune response.
The relapsing-remitting pattern of MS is thus regulated by cytokines and adhe-
sion molecules, not only in the central nervous system itself, but in the peripheral
immune organs. 
ABSTRACT
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1 INTRODUCTION
Multiple sclerosis (MS) is one of the most common disabling neurological dis-
eases in young adults. The cardinal pathological features are focal areas
(plaques) of demyelination and immune-mediated inflammation, usually
perivenular in orientation. MS patients often develop first symptoms during
their early 20’s and the course of the disease is life-long. The pathogenesis of
MS is still unclear, although a viral aetiology (possibly through an autoimmune
mechanism) has been proposed. 
The assumption that MS is an autoimmune-mediated disease is largely based
on the findings that its pathological changes in the CNS are similar to those
in an experimentally induced autoimmune disease: experimental autoimmune
encephalomyelitis (EAE) in rodents. However, the disease course of EAE is
mainly monophasic, in contrast to the typical chronic or relapsing-remitting
disease course of MS. 
With a modified immunization protocol, a novel model of MS-chronic relaps-
ing experimental autoimmune encephalomyelitis (CR-EAE) was established
in SJL mice (Fig.1). This new model is characterized by a chronic relapsing-
remitting disease course which resembles human MS more closely. In this
thesis, I have further investigated the cellular and molecular mechanisms under-
lying the development of CR-EAE. In particular, the patterns of certain
cytokines as well as cellular adhesion molecules (CAMs) in relation to the dis-
ease course of CR-EAE were addressed. 
INTRODUCTION
Pretreatment:
Injection of 3 mg MSCH, 0.2 mg M.tb
and 0.025 mg M. b in 0.05 ml PBS into
the left hind footpad.
Second injection:
Injection of 3mg/1.5 mg MSCH, 0.1 mg M. tb
and 0.125 mg M. b in water-oil emulsion into
the right hind footpad, Followed by an injection
of 0.2 mg pertussis toxin i.v.
Two-month interval
Fig. 1. Scheme of the induction of CR-EAE
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2 REVIEW OF THE LITERATURE
2.1. Multiple sclerosis
Multiple sclerosis (MS) is a demyelinating disease of the central nervous sys-
tem (CNS) that affects various parts of the brain and the spinal cord and causes
tremendous suffering to the affected individuals (1). It is the most common
neurological disturbance among young adults in populations of Northern
European origin (2). The chronic disease course of MS is unpredictable and
life-long. The patients often lose their ability to work and need considerable
extra nursing assistance in the worst cases. The various clinical manifestations
of MS, such as paralysis, reduced coordination, speech problems, visual, sen-
sory and mental disturbances, incontinence etc. are direct consequences of
the tissue damage in the CNS, but are typically pronounced during a relapse.
The tissue damage is due to perivenous demyelination of nervous tissue,
mononuclear cell infiltration as well as astrocytic gliosis (3). For unknown rea-
sons, MS affects women more frequently than men. Geographically, there is
an increasing gradient for MS from the Equator to the Northern hemisphere
(2). However, the commonly accepted belief that MS frequency in Europe is
directly related to latitude has been refuted by the many prevalence studies car-
ried out in Southern Europe since 1980, which show that MS prevalence in
this area is, in fact, much higher than had been believed (4). The new estimated
prevalence rates in continental Italy and Sicily since 1980 range from 32 to
58/100,000, those in Sardinia ranging from 59 to 103/100,000. This is much
higher when compared with a rate of 5 to 25/100,000 in European countries
from about 36 to 46˚ north latitude, based on prevalence studies carried out in
Italy between 1959 and 1975. MS not only causes physical disability but also
has a major adverse psychosocial and economic impact on the affected indi-
vidual, his family, and the society. 
Epidemiological data in Finland demonstrated an increased prevalence rate
of MS in recent years (5). It was also found that the increased prevalence is
mainly due to an increased incidence in western (Seinäjoki) and southern
(Uusimaa) Finland (5, 6), pointing to locally acting environmental factors. 
Epidemiological studies have suggested an interplay between genetic and envi-
ronmental factors in the aetiology of MS. A genetic component in MS was
indicated by several lines of investigation. First, in studies with monozygotic
Jinghui jang  30.10.2003  13:56  Sivu 13
14
twins, if one twin developed MS there was a nearly 30% chance that the oth-
er twin would also develop MS (7-9). However, one should keep in mind that
monozygotic twins are more likely to share a similar life style, which unavoid-
ably renders them exposed to mutual environmental factors. Second, there is
a much higher familial recurrence rate (about 15%) compared to a background
age-adjusted risk in the investigated population (about 0.3% ) (10-12). However,
the possibility that the higher familial recurrence rate is due to an exposure to
the same environmental factors within the family can not be totally excluded.
Third, there is an HLA association in MS patients with HLA DRw15, DQw6,
Dw2 in Caucasian Europeans and North Americans (13, 14) and a secondary
association with DRw15, DQw6, Dw2 in Swedish MS patients (15). Fourth,
descriptive data since 1980 indicates that ethnicity plays an important role in
determining European MS distribution (4). On the other hand, substantial
evidence supports an environmental contribution to the pathogenesis of MS.
Epidemiological data indicates that there is a latitude distribution in the inci-
dence of MS: The northern latitudes tend to have higher incidence of MS (2).
Furthermore, when individual countries were surveyed for the incidence of
MS, a clustering of MS cases was reported (6, 16-20). This clustering was also
seen when the same regions were resurveyed a generation later. Thus, Kurtzke
suggested that ”MS is intrinsically related to geography, and therefore MS can
be defined as an acquired, exogenous, environmental disease” (21). 
Several studies have suggested that infections may be the cause of MS. In par-
ticular, a viral aetiology for MS has been proposed for a long time (22-27).
Studies in Iceland indicated that there was an increase in the incidence of MS
following World Wars I and II when the British, Canadian and American sol-
diers occupied the country (28). Similarly, epidemiological surveys of the
Shetland-Orkney Islands and Faroe Islands demonstrated an increase in MS
following the Second World War, and the locations of the British troop encamp-
ments strongly correlated with the place of residence of all MS patients (29-35).
In fact, there were few, if any, documented cases of MS prior to 1943 in the
Faroe Islands. Furthermore, an increase in MS exacerbations has been found
in patients experiencing bacterial infections (36, 37). Likewise, it has also been
found that viral infections were often temporally related to exacerbations of
MS (24, 38-40). 
Further evidence supporting an infectious aetiology for MS comes from migra-
tion studies. It has been consistently reported that those who migrate before
adolescence develop MS at a rate similar to that of natives of their adopted
REVIEW OF THE LITERATURE
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country. Those who migrate after adolescence, on the other hand, seem to retain
the risk of their country of origin (41-48). These data indicate that there is a
susceptibility ”time window” during late childhood for the development of MS
later. During this time the individuals are assumed to catch some infectious
agents. Intriguingly, MS does not occur immediately after a clinical infec-
tion. A latent incubation period of about 15-20 years is needed before the onset
of MS (21, 49). The concept of a critical exposure time during late adolescence
for conceiving MS is further supported by a cluster study in Hordaland, Norway.
This study demonstrated that patients in the same birth cohort had lived clos-
er to each other than would have been expected between the ages of 13 and
20 (50). All in all, these data are consistent with the hypothesis that infections
early in life could subclinically prime genetically susceptible individuals for
MS (51). Interestingly, this view may also apply to insulin dependent dia-
betes mellitus (IDDM) (52). Another study on the Orkney islands identified
two clusters: the MS patients were found to have clustered in a time period at
least 21 years before onset, and again just before onset (53). The authors went
on to speculate that this finding may reflect exposure to the same agent at
two points in time or exposure to two different agents (Fig. 2). 
2.2 Experimental autoimmune encephalomyelitis (EAE)
2.2.1 Background
EAE is induced by immunization of animals with a neuroantigen emulsified
in complete Freund’s adjuvant (CFA). It is an inflammatory and demyelinat-
ing disease of CNS and has served as a prototype animal model for human MS
(54). The origin of this model can be traced to efforts to develop a vaccine for
the rabies virus. It was found that a small percentage of humans who received
Pasteur’s rabies vaccine suffered from encephalomyopathy (55), which
appeared to be due to the whole CNS homogenates in the vaccine rather than
to the rabies virus or infective contaminants (56). Subsequently, Koritschoner
and Schweinburg (57), and later Hurst (58), reported of a successful induc-
tion of paralytic disease in rabbits by a repeated injection of normal brain tissue.
However, no obvious pathological changes were present in the brains or spinal
cords of the paralysed rabbits. Rivers et al induced experimental allergic
encephalomyelitis (EAE) by multiple intramuscular injections of nonhuman
primates with rabbit brain homogenates or the concentrated alcohol-ether
extracts (59, 60). The EAE induced in rhesus monkeys by Rivers was charac-
REVIEW OF THE LITERATURE
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terized by an inflammatory reaction accompanied by demyelination. Shortly
after, Freund and McDermott developed a new technique of adding various
adjuvants as aquafor, paraffin oil and heat-killed tubercle bacilli (61) to the
antigens. This new immunization technique opened the way for the experi-
mental production of encephalomyelitis with a considerably reduced number
of injections. By using such a technique, antibrain antibodies in the monkey
REVIEW OF THE LITERATURE
Attraction of the first infection Secondary infection after 
durin late childhood between an ”incubation period”
10-15 years old    
Fig. 2. Two infections theory for the pathogenesis of MS
20 years old and more
Susceptibility time window Incubation period
Development of MS
10 years old 15 years old
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were produced (62). Shortly after, rapid production of acute EAE in Rhesus
monkeys (63, 64), guinea pigs and rabbits (65-68), following the injections
of brain tissue with adjuvants, was reported. EAE was also induced in other
species such as sheep, dogs and chickens (69). In 1949 Olitsky et al induced
demyelinating EAE in mice (70), thus establishing murine EAE as a model for
a CNS demyelinating disease, such as MS. For the first time, Ferraro report-
ed the production of chronic EAE in Rhesus monkeys with repeated injections
(71). Thereafter, a number of different EAE models have been reported (see
reviews (72, 73) ). 
For the past 40 years, rats and mice have proven extremely useful for inves-
tigating the pathogenesis of EAE. However, the disease induced in rats of the
Lewis strain is mainly acute, and most animals recover spontaneously.
Moreover, they are resistant to subsequent active EAE induction. Although
there is perivascular mononuclear cell infiltration in the spinal cord and the
brain stem, demyelination is minimal. In contrast, EAE induced in mice is char-
acterized by both mononuclear cell inflammation and demyelination, features
that resemble human MS (72). Another advantage for the use of mice to study
EAE is that there are many inbred and congenic strains. In addition, many
mouse-specific reagents are available for study of the genetic aspects and cel-
lular interactions associated with the disease (74). The susceptible strains of
mice, such as SJL/J and PL/J, are not resistant to reinduction of the disease.
Furthermore, it is possible to induce the chronic relapsing EAE in mice - a
model that resembles human MS more closely (75, 76). Based on the above
considerations, and because the current phamacotherapy of MS lies on
immunomodulation, the current studies were concentrated on analyzing the
immunopathogenesis of EAE in SJL/J mice. 
EAE is the most thoroughly studied animal model for human autoimmune dis-
eases, and much of our understanding of the pathogenesis of autoimmune
diseases have been derived from studies of EAE. Several reasons may account
for the popularity of EAE as a model for antigen-induced autoimmunity: (a)
EAE has been developed earlier than other models, (b) EAE is easily induced
in many species, (c) the clinical manifestations of EAE, namely paralysis and
loss of tail tone (rodents), appear apparent to most observers (77) and (d) myelin
basic protein (MBP), the primary autoantigen in EAE, abundant in CNS tis-
sues, is easy to extract and purify. In contrast with other autoantigens such as
acetylcholine receptor (experimental autoimmune myasthenia gravis) or col-
lagen (collagen induced arthritis), MBP is relatively small in size; murine MBP
REVIEW OF THE LITERATURE
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has a molecular weight of approximately 17 kDa. The small size of MBP has
facilitated the identification of its critical determinants. Recently, a proteolipid
protein and myelin oligodendrocyte glycoprotein (MOG) have been shown to
induce EAE effectively. Hitherto, a considerable amount of literature has been
generated following the first paper on EAE by Rivers (59). In the following,
those aspects of EAE that are relevant to this dissertation will be reviewed. 
2.2.2 Autoantigens used in the immunization 
Initially, brain homogenates or its crude extracts were used as the antigen for
immunization (57-59). It has been shown that heterologous brain tissue is
less efficacious than homologous brain tissues (78), and that it is possible to
induce EAE by endogenous brain tissue (79). These data suggest that the host
is not tolerant to certain self CNS antigens. Kabat suggested that the autoanti-
gens were located in the white matter, since injection of fetal CNS tissue,
lacking myelin, did not cause EAE (80). MBP, the major protein constituent
of myelin (approximately 30% of total protein), was identified as an encephal-
itogenic antigen in the CNS tissue (81, 82). MBP consists of a series of charge
isomers, resulting from posttranslational modifications (e.g., deamidation or
phosphorylation) (83). The predominant form of MBP has a molecular weight
of 18.5 kDa. In rodents, another MBP molecule of 14-kDa is produced in addi-
tion to the 18.5-kDa molecule as a result of differential RNA splicing of the
MBP gene (84). The amino acid sequences of MBP from various species have
been determined (85). 
MBP has been shown to induce acute EAE in mice, rats, guinea pigs, rabbits
and monkeys, as well as in humans accidentally injected during the course of
laboratory experiments (69). Encephalitogenic epitopes of MBP have been
identified by several investigators using different EAE models. The MBP pep-
tide H-Phe-Ser-Trp-Gly-Ala-Glu-Gly-Gln-Lys-OH causes EAE in guinea pigs
(86). The MBP peptide H-Thr-Thr-His-Tyr-Gly-Ser-Leu-Pro-Gln-Lys-OH caus-
es EAE in rabbits (87). The MBP peptide H-Phe-Lys-Leu-Gly-
Gly-Arg-Asp-Ser-Arg-Ser-Gly-Ser-Pro-Met-OH causes EAE in monkeys (88).
The MBP peptide H-Gly-Ser-Leu-Pro-Gln-Lys-Ser-Gln-Arg- Ser-Gln-Asp-
Glu-Asn-Pro-Val-Val-His-Phe-OH (89-91) causes EAE in rats. Guinea pig
MBP residues 68-86 and its corresponding synthetic peptides (YGSLPQK-
SQRSQDENPV) and synthetic peptides 73-86 (QKSQRSQDENPV) are
encephalitogenic in Lewis rats (74). Initial studies in mice demonstrated that
REVIEW OF THE LITERATURE
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MBP 1-37 and C-terminal 89-169 of guinea pig MBP cause EAE in inbred
mouse strains (92-94). It has been shown that SJL/J mice responded mainly
to the encephalitogenic determinant in peptide 89-169, whilst PL/J mice as
well as (SJL/JxPL/J) F1 mice responded primarily to an encephalitogenic deter-
minant within peptide 1-37 of guinea pig MBP (92, 95). By using overlapping
synthetic peptides, MBP residues 1-9 (ASQKRPSQR) were identified to be
the dominant PL/J epitope (96). The N-terminal alanine in native MBP is N-
acetylated, and the synthetic peptide induces EAE only when N-acetylated.
The encephalitogenic epitope for SJL/J mice was localized to residues 89-
101 (97), corresponding closely to the 87-99 epitope that is encephalitogenic
in Lewis and Buffalo rats. In addition, two minor determinants of mouse MBP
spanning residues 87-98 and 91-104 were found to induce EAE in SJL/J mice
(98). 
Another major protein of myelin is proteolipid protein (PLP). PLP is only found
in CNS myelin and it represents about 50% of the myelin protein. PLP is capa-
ble of inducing EAE in mice (99, 100). However, PLP is a hydrophobic protein
that has been difficult to isolate (101). Synthetic peptides of PLP have been
broadly used for the induction of EAE. Murine PLP peptide residues 103-116
(YKTTICGKGLSATV), 139-151 (HSLGKWLGHPDKF) and 178-191
(NTWTTCQSIAFPSK) were found to be encephalitogenic in SWR/J (H-2q)
and SJL/J (H-2s)mice (102, 103). Minimum sequence requirements within
these PLP peptides for induction of EAE were also determined (104). PLP
43-64 (EKLIETYFSKNYQDYEYLINVI) was found to be encephalitogenic
in PL/J mice and induced a relapsing disease (105). Three overlapping syn-
thetic peptides corresponding to the region of PLP residues 217-240 were
encephalitogenic for Lewis rats, provided that the peptides were N-acetylated
(106). 
Recently, myelin oligodendrocyte glycoprotein (MOG) has received consid-
erable attention from researchers as a prominent autoantigen for induction of
EAE (107). MOG is a quantitatively minor oligodendrocyte-specific protein
that is preferentially incorporated into the outermost surface of the myelin
sheath (108), where it accounts for only 0.01-0.05 wt% of the membrane pro-
tein (109). The mature MOG protein is a highly conserved 218-amino acid
member of the immunoglobulin superfamily (110). The putative N-terminal
Ig domain (MOGigd) is located at the outermost surface of the myelin sheath,
making it an ideal target for antibody-mediated demyelination (111). It has
been shown that many MOG peptide sequences contain determinants that are
REVIEW OF THE LITERATURE
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encephalitogenic in several different species/strains (rats, mice and monkeys
etc.). Compared with other autoantigens, MOG is unique in that it is the only
CNS autoantigen known to induce both an encephalitogenic T-cell response
and a demyelinating autoantibody response in EAE. EAE can be induced in
many different inbred mouse strains using MOGigd and synthetic MOG pep-
tides. MOGigd induces severe chronic EAE in DBA/1, C57l/6 and NOD/Lt
mice, but a somewhat milder disease in SJL/J and Biozzi AB/H mice (112,
113). MOG35-55 has been used to induce a severe, chronic EAE in Biozzi AB/H
(H-2dq1), PL/J (H-2u), C57Bl/6 (H-2b), C3H.SW (H-2b), and NOD/Lt (H-2g7)
mice, while MOG92-106 induces EAE in SJL/J and A.SW mouse strains (H-
2s) (112, 114-117) ; and MOG 79-96 induces severe EAE in H-2q mice (113).
In SJL/J mice, it has been shown that MOGigd is a far more potent encephal-
itogen than MOG92-106 and PLP130-151 (111). EAE induced in SJL/J mice with
MOGigd is characterized by large cellular infiltrates reaching deep into the
parenchyma associated with large areas of demyelination and extensive axon-
al damage (111). 
In addition to MBP, PLP and MOG, the list of encephalitogenic components
of myelin also includes myelin associated glycoprotein (MAG) (118), myelin
oligodendrocyte basic protein (MOBP) (119) and S-100β (120). 
2.2.3 Role of killed Mycobacterium tuberculosis bacteria
Killed M. tuberculosis - a major component of CFA (121) is one of the most
potent adjuvants. Lewis and Loomis discovered that living, virulent tubercle
bacilli injected into the peritoneal cavities of guinea pigs enhanced antibody
formation to various antigens subsequently introduced by the same route (122,
123). This adjuvant activity of M. tuberculosis has been confirmed by many
other investigators subsequently. 
The smallest subunit of the mycobacterial cell wall that retains adjuvant activ-
ity is N-acetyl muramyl-L alanyl-D isoglutamine, called muramyl dipeptide
(MDP) for short (124). Muramyl dipeptide is able to replace killed mycobac-
teria in CFA for the induction of both humoral and cellular immunity (124).
The adjuvant activity of mycobacteria could be due to the recognition of defined
microbial components by phylogenetically ancient receptors present on acces-
sory cells (125). This recognition signals the danger of infection and elicits
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an adaptive immune response (126). When an autoantigen is presented by
accessory cells that are simultaneously activated by microbial components, an
autoimmune response may be initiated through a bystander mechanism (127)
(Fig. 3). Indeed, it has been shown that CFA (killed mycobacteria plus paraf-
fin oil) induced Th1 cytokines whilst paraffin oil-the incomplete Fruend’s
adjuvant (IFA) alone induced Th2 cytokines (128-130). However, the co-stim-
ulation theory failed to explain why autoimmune diseases are so rare whilst
infections are so common. Neither can it explain the chronicity - the hallmark
of all the clinical autoimmune diseases. 
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Fig. 3. Schematic illustration of the bystander mechanism for the develop-
ment of autoimmune T cells. A: anti-microbe effector T cells developed
after microbial Ag is presented to naive T cells by APC. B: Presentation of
self-Ag alone by APC to naive T cells resulted in either a development of
regulatory T cells (Tr) or apoptosis of self-Ag specific T cells. C: when
self-Ag is presented together with microbe-Ag by the same APC, auto-
immune T cells develops.
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In searching for substitutes for M. tuberculosis, several Gram-positive and neg-
ative organisms have been tested and found to be effective in the induction of
EAE (131). It was found that practically all mycobacteria (M. butyricum, for-
tuitum, phlei, smegmatis, and tuberculosis H37 Ra) are equally good as M.
tuberculosis (131, 132). Nevertheless, killed M. tuberculosis has been tradi-
tionally used in the induction of EAE. We have used both M. tuberculosis and
M. butyricum as constituents of CFA in our studies (76). 
While both neuroantigen and killed mycobacteria are essential for a suc-
cessful induction of EAE (133), it is of interest to note that their proportion
to each other is more important than their absolute quantity. Shaw et al first
presented without discussion or comment data indicating a crucial role of the
ratio between neural antigen and killed M. tuberculosis (134). Production
of EAE was affected adversely not only by a reduction in the amount of killed
M. tuberculosis as adjuvant, but also by its increase beyond a certain criti-
cal level. The same held true for neural antigen. In other words, the optimal
induction of EAE depends on the optimal proportion between neuroantigen
and killed mycobacteria (132, 133). In the induction of EAE in guinea pigs,
the threshold amount (minimum amount for effective disease induction) for
brain antigen was determined to be around 0.03 to 0.05 mg (dry weight), and
about 0.02 mg for M. butyricum and about 0.1 mg of M. tuberculosis. The
threshold amount for the spinal cord antigen is just below 0.06 mg, but about
ten times more is required for the development of maximal severe EAE. As
little as 0.01 mg of M. tuberculosis can serve as an adjuvant when spinal cord
is used as an antigen, but at least five times more is required for maximal
disease (133). 
At the moment, the mechanism underlying this interesting phenomenon is
unclear. Further studies are warranted to look into the changes of various
immunological parameters caused by changes in the ratio between neuroanti-
gen and killed mycobacteria in the induction of EAE. 
2.2.4 Role of paraffin oil 
The use of paraffin oil (hydrocarbons, alternatively called mineral oil) as an
adjuvant has a long history. In 1899, Grassberger found that the cellular reac-
tion to mycobacteria was enhanced by the addition of butter and even more
so by paraffin oil (135). With the aid of emulsifying agents (136), Freund and
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McDermott in 1942 immunized Guinea pigs with horse serum emulsified in
paraffin oil containing killed tubercle bacilli in a water-in-oil emulsion (61),
thus starting the era of complete Freund adjuvant - CFA. Soon after, CFA
became popularly used for a rapid induction of EAE (63, 64) as well as other
experimental autoimmune diseases. 
The mode of action of paraffin oil as an adjuvant is not clear. It has been pos-
tulated that the effect of paraffin oil is to localize the antigen in its initial depot,
resulting in a slow release of the antigen (137). However, the effect of paraf-
fin oil can not merely be a depot effect. Oil of plant origin can also form stable
emulsions with antigen, but it has not been found to substitute paraffin oil,
which is resistant to enzymes available in the animal economy (138). On the
other hand, it has also been shown that EAE can still be induced when the
injection sites are removed only one hour after the injection of neuroantigen
emulsified in CFA (139). Freund proposed that the effect of paraffin oil is to
bring a relatively large amount of antigen into contact with phagocytic mononu-
clear cells. Additionally, the creation of numerous foci, remote from the site
of injection, in the lymph nodes and lungs that may act as sources of anti-
genic stimuli, might also be important (139). 
2.2.5 Role of Pertussis toxin
Pertussis toxin (PTX) is the major protein toxin produced by virulent strains
of Bordetella pertussis, the organism that causes whooping cough (140). PTX
has multifaceted effects that include induction of lymphocytosis, stimulation
of insulin secretion, enhancement of vascular permeability, inhibition of lym-
phocyte recirculation, mitogenic effects on T and B cells, enhancement of
IgE production and sensitization to histamine. It has thus been variously referred
to in the literature as lymphocytosis-promoting factor, islet-activating pro-
tein, histamine-sensitizing factor and pertussigen (reviewed in (141) ). 
There has been a long history of using pertussis as an adjuvant in the enhance-
ment of experimental autoimmune diseases elicited by immunization of
laboratory animals with the appropriate tissue antigens. Such models include
e.g. experimental autoimmune orchitis (EAO) (142), experimental autoim-
mune uveoretinitis (EAU) (143) and EAE (144). As little as 20 ng of PTX
enhanced the induction of EAE in rats (145). In mice, normally 100-200 ng
of PTX is injected intravenously and this dose is well tolerated. 
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The mechanism by which PTX promotes the development of experimental
autoimmune diseases is not fully understood. Early studies by Linthicum and
Sudweeks (146-148) demonstrated the effects of PTX in the EAE model to
histamine sensitization genes and the disruption of the blood-brain barrier
(BBB). Based on these observations, it has been widely assumed for over 20
years that the enhancing effect of PTX on the induction of autoimmunity is
due to the breakdown of the BBB and a subsequently facilitated infiltration
of inflammatory cells into a target organ. However, this dogma can not be con-
clusive. Two concurrently occurring events (here, the enhancement of EAE
and increased BBB permeability by PTX) do not necessarily have a causal
relationship. One may well argue that the enhancing effect of PTX on EAE
was a result of hypoglycaemia caused by PTX (141). It has been known that
the encephalitogenic T cells take about 7 days to develop and migrate into the
CNS immediately before the onset of EAE (around 9 days after the immu-
nization) (149). If the enhancement of vascular permeability is indeed a major
mechanism, the effect of PTX should be maximal when it is administered at
the time of effector cell migration to the CNS. However, it has been shown
that PTX was most effective when given i.v. from 1 day before to 5 days after
injection of MSCH in CFA, when a uniform and severe disease was induced
11-13 days after immunization of mice (150). Administration of PTX 12 days
after immunization was not effective (150). McAllister found that treatment
of recipient rats with PTX at the time of uveitogenic cell transfer delayed the
onset of EAU (143). Likewise, it has also been shown that administration of
PTX to mice concurrently with adoptive transfer of activated uveitogenic T
cells or 1 week after immunization with retinal Ag in CFA not only failed to
enhance but actually completely blocked the development of EAU (144). These
data support the notion that PTX plays its enhancing role in the early phase
of the development of autoimmune T cells. 
2.2.6 Acute vs chronic relapsing EAE 
The most intensively studied EAE models have been established in rodents by
a single immunization regimen and the disease course is usually acute. Chronic
relapsing EAE (CR-EAE) resembles MS more closely than acute EAE.
Spontaneous relapses of EAE (71, 151, 152) have been reported to occur in a
small proportion of sensitized animals. Chronic (153) and relapsing (154, 155)
forms of EAE induced by single sensitization of immature guinea pigs have
also been reported. Similar work has also been done with hamsters (156), Lewis
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rats (157) and Biozzi mice (158). Disease relapse was also induced by low-
dose cyclosporin-A treatment in a Lewis rat EAE model (159). However,
relapses in these models were either rare or late at the onset. Chronic relaps-
ing EAE has been established in mice also by adoptive transfer of myelin basic
protein-sensitized T cells (160) or T-cell clones (161). However, the onset of
relapse is late (40-50 days) in the former model, and only few mice survive in
the latter one, and the frequency of relapse is low. The cell transfer models
have limited relevance to the human disease, since it is unlikely that patients
have ever been transferred with autoimmune T cells. When the pertussis vac-
cine was included in the immunization, a delayed form of relapsing EAE was
induced (162, 163). However, only few relapses were recorded in a prolonged
follow-up. It was also reported that bacterial superantigen SEB induced relaps-
es of paralytic disease in mice that were in clinical remission (164). A. M.
Brown established relapsing EAE in SJL/J mice by two injections of neu-
roantigen emulsified in CFA at 1 week intervals (75). This regimen has been
broadly used for the induction of CR-EAE thereafter. However, the first relapse
in this model appeared also rather late (30 to 50 days) and only 2 to 3 relaps-
es were recorded during the 6 month follow-up. Occasionally, the majority (up
to 90%) of mice died of the first disease attack. 
2.3 Cytokine expression in EAE
Cytokines are small protein or glycoprotein messenger molecules that convey
information from one cell to another (165), and play an important role in inflam-
mation and autoimmune responses (166). CD4+ T lymphocytes can develop
into Th1 or Th2-type cells, which are characterized by their abilities to produce
different cytokines (167). Th1 cells produce IL-2, IFN-γ and TNF-β whereas
Th2 cells produce IL-4, IL-5 and IL-10. These two groups of cytokines are
often antagonistic to each other in their effects (168) (Fig. 4). In EAE - a CD4+
T cell - mediated autoimmune disease (77), Th1-type cytokine expression in
CNS as well as in the peripheral lymphoid organs has been reported to be asso-
ciated with disease progression, whereas the production of Th2-type cytokines
has been correlated with disease recovery (169-172). Similarly, oral tolerance
to myelin basic protein and a natural recovery from EAE are associated with
a down regulated production of inflammatory cytokines and upregulation of
transforming growth factor ß and IL-4 (172-174). Both IL-4 and IL-10 are
required for the induction of oral tolerance (175). The brains from EAE sus-
ceptible SJL mice contain mainly IL-2 and IFN-γ positive cells, whereas the
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brains from EAE resistant B.10 S mice have fewer cell infiltrates, which pre-
dominantly express IL-4 and IL-10 (176). Similarly, it has also been found that
mice with IFN-γ receptor deficiency are less susceptible to experimental autoim-
mune myasthenia gravis (EAM) (177). The regulatory roles of IL-4 and IL-10
have further been strengthened by findings showing that IL-4 and IL-10-defi-
cient mice have developed a more severe EAE (178, 179), and a local production
of IL-4 and IL-10 in the brain prevented the induction of EAE (180, 181). Taken
together, these studies suggest that the Th1 cytokines are involved in disease
progression, whereas the Th2 cytokines promote disease recovery. 
In contrast to the above, there is now ample evidence that challenges the
Th1/Th2 paradigm in EAE/MS. For example, myelin basic protein-specific
Th2 cells were found to cause EAE in immunodeficient hosts rather than to
protect them from the disease (182). Mice rendered deficient for IL-2 by gene
targeting developed a generalized autoimmune disease (183). IFN-γ has been
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shown to suppress EAE, and IFN-γ-knockout mice had a more severe EAE
(184-187). However, these findings were contradictory to demonstrations that
the treatment of patients suffering from MS with IFN-γ led to an exacerbation
of the disease (188). It has been reported that a local production of IL-10 by
islet cells accelerated immune-mediated destruction of β cells in nonobese dia-
betic mice (189). Also, recombinant IL-4 has been found to aggravate
experimental autoimmune uveoretinitis (EAU) in rats (190). Recently, there
have been reports showing that both Th1 and Th2 cytokines are produced by
the peripheral lymphoid organs, peripheral blood mononuclear cells as well
as by immune cells in the CNS in EAE (191, 192). Similarly, both Th1 and Th2
cytokines have been found to be produced in patients suffering from MS (193,
194). However, little information is available on the cytokine mRNA expres-
sion profiles in the peripheral lymphoid organs during relapse or remission of
MS or EAE. 
2.4 Expression of cellular adhesion molecules (CAMs) in EAE
The lymphoid system is functionally compartmentalized into discrete primary
(bone marrow and thymus), secondary (lymph nodes, gut-associated lymphoid
tissues and the spleen) and tertiary (the remainder of the body’s tissues) lym-
phoid organs (195). Lymphocytes produced in the primary lymphoid organs
migrate to the secondary lymphoid organs where antigen presentation takes
place. The activated antigen-specific lymphocytes seek out and localize to par-
ticular tissues to elicit a local immune response. This process of lymphocyte
trafficking is tightly regulated by the differential expression of cellular adhe-
sion molecules (CAMs) (195-198). Furthermore, CAMs such as LFA-1 (by
interaction with its ligand-ICAM-1), provide an important costimulatory sig-
nal for T cell receptor-mediated activation of resting T cells (199-201). In
this part, only a few CAMs that have been studied in this thesis are reviewed. 
Among identified CAMs, LFA-1 is one of the most thoroughly studied (202).
LFA-1 can mediate the adhesion of leukocytes to endothelial cells through
binding to ICAM-1 (203-206). The structure and functions of LFA-1 have been
thoroughly studied (202, 207-209). LFA-1 expression becomes upregulated on
infiltrating mononuclear cells and some resident cells in the brain of MS patients
and in animals with EAE (193, 210-212). Lymphocytes from either cere-
brospinal fluid (CSF) or the blood of MS patients express increased levels of
CAMs including LFA-1 and CD44 (213). Parallel to the above reports, anti-
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LFA-1 therapy has been shown to prevent EAE in mice and rats (214-216).
Similarly, treatment with antibodies against LFA-1 and ICAM-1 prevented the
adoptive transfer of murine Sjögren’s syndrome into severe combined immun-
odeficient mice (217). In models of organ transplantation, injection of
anti-LFA-1 antibody has been shown to dramatically prolong the survival of
the grafts (217-219). However, it has also been reported that anti-LFA-1 ther-
apy could actually exacerbate EAE (220, 221). 
CD44 is a pro-inflammatory cell surface molecule participating in cell hom-
ing into target organs (195). CD44 is expressed by a wide variety of cell types
and not just leukocytes (222). Monoclonal antibodies to different epitopes of
CD44 interfere with a number of distinct lymphocyte adhesive interactions
(223), and polyclonal anti-CD44 antibodies block cell binding to high endothe-
lial venules (HEV) (224). Memory T cells display more CD44 than naive T
cells (225). The expression of CD44 is increased on lymphocytes from either
the CSF or blood of MS patients (213), suggesting a possible role for CD44
in the autoimmune demyelinating disease. In collagen II-induced arthritis, treat-
ment with anti-CD44 antibodies has been shown to be beneficial (226-229).
However, in EAE anti-CD44 therapy has yielded controversial results. While
it has been shown that CD44 was involved in selective leukocyte extravasa-
tion during the inflammatory central nervous system disease and anti-CD44
treatment proved beneficial in EAE (230, 231), others showed that such a treat-
ment had no effect on lymphocyte binding to blood vessels (232) and even had
an exacerbating effect on EAE (233) and experimental thyroiditis (234). At the
present time, it is difficult to interpret these controversial results. 
ICAMs are members of the immunoglobulin superfamily and serve as cellu-
lar ligands for the leukocyte integrins (198). ICAM-1 is present on leukocytes,
endothelial cells and many other tissues, and is perhaps the most important
binding ligand for LFA-1 (208). Its expression is upregulated on activated cells
and inflamed tissues. On the other hand, ICAM-2 expression is relatively sta-
ble (198). VCAM-1 is the endothelial ligand for α4β1 integrin (or VLA-4). Its
expression is inflammation induced and heterogeneous (235, 236), suggesting
the possibility of tissue-selective function (195). So far, most of the studies
on the role of ICAMs during MS have relied on immunohistochemical analy-
ses of the expression of ICAMs during the different stages of disease on autopsy
CNS material or on blood or CSF-derived lymphocytes from patients with MS
(210). Upregulation of ICAM-1 and VCAM-1 in typical MS lesions has been
observed (193, 211). The levels of both soluble ICAM-1 and VCAM-1 in CSF
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were increased during MS relapse (237, 238). In EAE, upregulation of ICAM-
1 and VCAM-1 in the CNS tissue coincided with the immigration of CD4+
lymphocytes, while downregulation coincided with their emigration (239). In
relapsing EAE, ICAM-1 is expressed intensely by vascular endothelium dur-
ing the acute phase, less intensely during relapses, and at diminished levels
during remission (240, 241). On the other hand, VCAM-1 mRNA levels were
elevated in the spinal cord only at the end of the acute phase of EAE (242).
Interestingly, it has been reported that VCAM-1 was expressed at higher lev-
els in chronic MS lesions, while ICAM-1 was more uniformly expressed in
lesions of all ages (193, 243). Moreover, increases in soluble VCAM-1 but not
in ICAM-1 correlated with a decrease in MRI lesions in MS patients treated
with interferon -β1b (244). These findings point to the possibility that VCAM-
1 expression is involved in the recovery of the disease. Despite the fact that
the expression and role of adhesion molecules have been a subject of studies
focusing on the EAE/MS affected CNS, there is little information of the nat-
ural expression levels in the peripheral lymphoid tissues modulating the disease
process. 
2.5 ICAM-5 
ICAM-5 (telencephalin) was first identified as a 130-kDa type I integral mem-
brane glycoprotein (245). It has been reported that ICAM-5 is expressed
exclusively within the telencephalon of mammalian brains, by certain subsets
of neurons (245-248)
.
Its expression is initiated in the newborn, and increas-
es during postnatal CNS maturation in parallel with dendritic elongation and
branching (246, 247). Because it is able to induce dendritic outgrowth (249),
ICAM-5 has been suggested to function in the synaptogenesis in the devel-
oping mammalian brain.
However, the fact that ICAM-5 binds to the integrin receptor CD11a/CD18
(LFA-1) which mediates leukocyte adhesion (249, 250), and that the CSF con-
centration of sICAM-5, the soluble form of ICAM-5, was significantly
increased in encephalitis (251), suggests that ICAM-5 might function as a medi-
ator of communication and adaptation in the neuroendocrine and immune
systems (252). The role of ICAM-5 in EAE has not been studied earlier, but
the CSF concentration of ICAM-5 in human MS was not different from the
control level (251). 
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2.6. Dendritic cells
Dendritic cells (DCs) are a sparsely distributed, migratory group of bone-mar-
row-derived leukocytes that are specialized for the uptake, transport, processing
and presentation of antigens to T cells (253). The function of DCs, as exempli-
fied by the Langerhans cells of skin, is that the DCs collect foreign antigens in
peripheral sites, process the antigens, migrate to the T cell areas of lymph nodes,
and then mature into a form competent to stimulate an immune response by those
T cells that recognize the MHC-presented foreign antigenic peptides (253). 
Distinct subtypes of DCs were initially more evident among mouse DCs than
among human DCs, because of the ready availability of different murine mark-
ers not present on human DCs. Mouse DCs that are classed as ”mature”
expresss CD11c (the integrin-α chain) and the co-stimulator molecules such
as CD80, CD86 and CD40, and have moderate to high surface levels of MHC
II. The T-cell markers CD4 and CD8 are also expressed on mouse DCs. CD11b
(the integrin αM chain of Mac-1) and the interdigitating DC marker CD205
(originally known as NLDC-145) are also expressed by mouse mature DCs
(254). Using these surface markers, five DC subtypes are consistently found
in the lymphoid tissues of uninfected laboratory mice (Table 1). Mouse spleen
contained predominantly two DC populations in equal proportions (255). 
The activation of the adaptive immunity starts when leukocytes recognize anti-
gen peptides presented by the antigen presenting cells (APCs), such as dendritic
cells (DCs), macrophages and B cells, in the context of MHC class I or II mol-
ecules. DCs express accessory molecules including LFA-3/CD58,
ICAM-1/CD54, B7-2/CD86 that interact with receptors on T cells to enhance
adhesion and signalling (256). Different co-stimulatory molecules on DCs
affect the development of T cells in different ways. For example, microbial
products may activate DCs through binding to Toll-like receptors (257, 258),
thus resulting in the up-regulation of MHC class II and costimulatory mole-
cules (CD80/CD86), and the development of pathogen-specific T cells. On the
other hand, self antigens are usually not able to stimulate DCs to express those
molecules that are induced by microbial products. As a result, self-antigen pres-
entation by DCs to T cells in the lack of certain co-stimulatory molecules
may actually lead to the development of regulatory T cells that down-regu-
late the autoimmune response. Studies on the role of DCs in MS are still limited.
In particular, DCs in the peripheral immune organs could play a pivotal role
in disease modification. 
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2.7 Immunotherapy of MS
Until recently, no definitive therapies aimed at reducing attacks and slowing
the disease process of MS have been available. However, among currently
available therapies, Interferon-beta and glatiramer acetate (copolymer 1) have
proven to have a modest effect on relapsing-remitting MS (RRMS). 
β-interferon. In the belief that MS may be caused by a latent viral infection of
the CNS, interferons (IFNs) have been tested, and IFN-β was found effective
in the treatment of MS when administered intrathecally (259). The develop-
ment of recombinant IFN-β and the demonstration of efficacy when
administered via the subcutaneous route paved the way for large-scale clini-
cal application. Recombinant IFN-β preparations approved for RRMS are
interferon beta-1-b (Betaseron®) and interferon beta-1-a (Avonex®, Rebif®).
However, the benefits have been only modest. The preparations were appli-
cable only to patients with relapsing-remitting disease, and the safety and
efficacy have been demonstrated only over a short period relative to the typi-
cal course of MS (260). Besides, neutralizing antibodies against IFN-β develop
in some patients and are associated with reduced clinical and magnetic reso-
nance imaging (MRI) efficacy (261). The exact mechanism of the action of
IFN-β in MS is unknown. However, it has been reported that IFN-β suppresses
T cell proliferation and inhibits T cell migration from the systemic circula-
tion into the CNS, and alters the cytokine profile from proinflammatory Th1
to the relatively anti-inflammatory Th2 response (262). It has also been report-
ed that IFN-β inhibits CD40-induced production of IL-12 by dendritic cells
(263). 
Glatiramer acetate. Glatiramer acetate was initially synthesized under the name
copolymer 1 as a potential encephalitogen for the induction of EAE, but was
found to do the opposite - to inhibit the induction of EAE in guinea pigs (264).
It was later found to suppress or ameliorate EAE in a number of species, which
led to trials in MS. The phase III trial in RRMS showed that glatiramer acetate
had a similar efficacy to that of β-interferon in terms of reducing the relapse
rate in RRMS (265). In addition, there was evidence for a beneficial effect on
disability progression in patients with RRMS. However, no significant bene-
fit was found on sustained disability progression (265). The mechanism of
action of glatiramer acetate is also unclear. Thus, its activity has also been
attributed to a shift from Th1 to Th2 predominance (266). 
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In addition to IFN-β and glatiramer acetate, mitoxantrone has been approved
for RRMS as well as for secondary progressive MS (SPMS). This was based
on positive outcomes from European studies (267), despite equivocal previ-
ous trials (268). 
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3 AIMS OF THE STUDY
To study the pathogenesis of a complicated human illness like MS, proper ani-
mal models are needed to represent the multiple facets of the disease. The
general aim of this study was to establish a mouse model that resembles human
MS more closely than classical EAE. Using different laboratory techniques,
the cellular and molecular disease mechanisms in this model were investigat-
ed. 
Specifically, the aims of the study were the following: 
1. To establish the methodology for quantification of mRNA expression for
cytokines as well as adhesion molecules (I)
2. To establish a mouse model that can resemble human MS closely (II)
3. To study the effect of memory responses in peripheral immune organs on
the development of CR-EAE (III)
4. To study the expression of different cytokines and CAMs in the peripheral
lymphoid organs of mice with CR-EAE (IV)
5. To study the expression of ICAM-5, a characteristic neural adhesion mole-
cule, on immune cells and during disease evolution of CR-EAE (V)
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4 MATERIALS AND METHODS 
4.1 Animals 
SJL (SJL/Ola/Hsd) mice studied at the Dept. of Virology, University of Turku,
were bred and kept at the animal facilities of the University of Turku. For the
experiments performed at the University of Tromsø and the Krakow Institute
of Pharmacology, Polish Academy of Sciences, female SJL (SJL/Ola/Hsd) mice
were purchased from Harlan UK Ltd. (Bicester, England). Mice were kept at
the animal facilities of the University of Tromsø, Tromsø, Norway, and of the
Krakow Institute of Pharmacology, Polish Academy of Science, Krakow,
Poland. The experiments were carried out in accordance with the ethical guide-
lines for animal research in the respective countries and institutes. 
4.2 Adjuvants
Killed Mycobacterium tuberculosis (M. tb), Mycobacterium butyricum (M. b)
and incomplete Freund’s adjuvant (IFA) were obtained from Difco Laboratories
(Detroit, MI, USA). Complete Freund’s adjuvant (CFA) was generated by
adding 80.0 mg of M. tb and 10.0 mg of M. b to 10.0 ml of IFA. Pertussis tox-
in was purchased from List Biological Laboratories (Campbell, CA, USA). 
4.3 Neuroantigen and control antigen
Mouse spinal cord homogenates (MSCH) and mouse heart homogenates (MHH)
were produced by homogenizing spinal cords and hearts from 2- to 4- month-
old SJL mice in PBS and lyophilized. When used, MSCH was dissolved in PBS
and kept on ice for 20 minutes. This MSCH suspension was emulsified with
an equal volume of CFA. 25 µl of the antigen emulsion was injected into the
hind footpads of mice.
4.4 Semliki Forest virus and reagents for in vitro cell culture
An avirulent mutant strain of Semliki Forest virus (SFV-A7) was obtained from
Dr. H.E. Webb (Neurology Unit, Department of Neurology, Rayne Institute, St
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Thomas’ Hospital, London, UK). The virus was propagated in a mouse brain
cell line-MBA-13. Virus stocks were titrated by a standard plaque assay method
and aliquots stored at -70˚C. Lipopolysaccharide from Escherichia coli was
purchased from Sigma (L-8399) (St Louis, MO, USA). The round bottom tis-
sue culture tubes were from Nunc (Roskilde, Denmark). 
4.5 Antibodies and agents for immunohistochemistry and
flow cytometry
A rabbit polyclonal antiserum against the extracellular part of ICAM-5 was made
by using ICAM-5 (D1-D9)-Fc as an immunogen as described previously (Tian
et al. 1997). Goat anti-rabbit immunoglobulin-specific polyclonal antibody
(FITC), rat anti-mouse CD3 (R-PE) and CD19 (PerCP) monoclonal antibod-
ies, hamster anti-mouse CD11c (APC) and their control monoclonal antibodies
were all from BD Biosciences Pharmingen (San Diego, CA, USA). MACS
microbeads conjugated with hamster anti-mouse CD11c and rat anti-mouse
CD11b monoclonal antibodies were purchased from Miltenyi Biotec (Bergisch
Gladbach, Germany). DNase I was from Roche Diagnostics GmbH (Mannheim,
Germany). Collagenase was purchased from Sigma Chemical Co (St. Louis,
MO, USA). The three-step avidin-biotin complex/horseradish peroxidase method
was from ABC, Vectastain, Vector Laboratories (Burlingame, CA). 
4.6 Reagents for RNA preparation, DNA isolation, 
PCR reaction and In situ hybridization
Guanidine thiocyanate was purchased from Sigma. Phenol and chloroform were
obtained from Amresco (Solon, OH, USA). SuperScriptTM choice system for
cDNA synthesis was purchased from GIBCO BRL, Life Technologies Inc.
(Rockville, MD, USA). AmpliTaq Gold DNA polymerase was from Perkin
Elmer (Branchburg, NJ, USA). The QIAGEN plasmid purification kit,
QIAquick gel extraction kit and QIAquick PCR purification kit were from QIA-
GEN, (Valencia, CA, USA). Nylon membrane (Gene Screen Plus) was
purchased from NEN® Research Products (Boston, MA, USA). SeaPlaque low
gelling temperature agarose was from FMC (Rockland, ME, USA). The [α-
32P] dCTP was purchased from NEN Life Science Products (Boston, MA,
USA). Agarose and DNA random primed labeling kit were products of
Boehringer Mannheim (Mannheim, Germany). The phosphoimaging system
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used for radioactivity quantification was Fujifilm BAS-2500, Fuji Photo Film
Co., Ltd (Tokyo, Japan). SDS (sodium dodecyl sulphate), EDTA (ethylene-
diaminetetraacetic acid), Tris-HCl, yeast tRNA, NaAc, HCl, NaCl,
paraformaldehyde, proteinase K, TEA (triethanolamine), acetic anhydride,
RNase A, Denhardt’s solution, dextran sulphate were all from Sigma. 1.4-dithio-
DL-threitol (DTT) solution was purchased from Fluka Chemie (GmbH-9471,
Buchs, Switzerland). Riboprobe (SP6, T3, T7) RNA labeling kit was from
Promega (Madison, WI, USA). NICKTM columns were from Amersham
Pharmacia Biotech AB (Uppsala, Sweden). Xylene was from YA-Kemia Oy
(Helsinki, Finland) and formamide from Sigma-Aldrich Laborchemikalien
GmbH (Seelz, Germany). Kodak NTB-2 emulsion, Kodak developer and fix-
er was from Eastman Kodak Company (Rochester, NY, USA). Ammonium
acetate was from E. Merck (Darmstadt, Germany). 
4.7 In vitro stimulation of murine splenic cells with A7-SFV
and lipopolysaccharide
4.7.1 Preparation of splenic cells
Six-week-old SJL mice were sacrificed by cervical dislocation and spleens were
collected under sterilized conditions. The spleens were minced and squeezed
through a sterilized steel mesh. After lysing the red blood cells in a buffer (0.15
M of NH4Cl, 1.0 M of KHCO3, 0.1 mM of EDTA), the cells were washed twice
in RPMI-1640. Twenty million splenic cells in 5 ml of RPMI-1640 supple-
mented with 10% inactivated fetal calf serum (FCS) and 0.01 mg/ml gentamycin
were cultured at 37˚C in 15 ml round bottom tissue culture tubes in a 5% CO2
atmosphere for 1 h before virus and/or LPS were added. 
4.7.2 Stimulation of splenic cells in vitro
For virus treatment, 20 million mouse splenic cells were incubated with SFV-
A7 virus at multiplicities of infection (m.o.i.) of 5 in 2 ml of culture medium
for 1 h and then washed once in fresh culture medium. For LPS stimulation,
10 ng/ml of LPS was added to the culture. After 1 h, the cells were washed
once, centrifuged and the cell pellet was suspended in 5 ml of fresh culture
medium containing 10 ng/ml of LPS. For a combined treatment with virus
and LPS, the cell preparation was handled as described for LPS treatment except
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that SFV-A7 was added at 5 m.o.i. at the beginning and left to absorb for 1 h.
Control cells were also washed once after 1 h and re-suspended in 5 ml of fresh
medium. Cultured cells were harvested after 1, 3, 6 and 12 h with duplicate
samples for each time point. In another experiment, SFV-A7 virus was added
at 5 m.o.i. in 3 h before (-3 h) or after (+3 h) LPS and allowed to absorb for 1
h. The cells were then washed and suspended in fresh culture medium con-
taining 10 ng/ml of LPS and cultured for another 3 h before harvesting. At the
end of each experiment, the cultured medium was centrifuged and the total
RNA was prepared from the cell pellets as described in 4.14. 
4.8 Induction of acute EAE
Acute EAE was induced in SJL mice by a single injection regimen. Female
SJL /J mice were injected with MSCH at a various doses (from 0.12 - 3.0
mg), together with either 100 µg of M. tb/12.5 µg of M. b or 200 µg of M. tb/25
µg of M. b, emulsified in paraffin oil (water:oil at 1:1 v/v). Immediately after
the injection of MSCH emulsion, 200 ng of pertussis toxin was injected i.v.
through the tail vein. The mice were checked daily and the disease index was
recorded for up to 3 months. 
4.9 Induction of chronic relapsing EAE (CR-EAE)
4.9.1 Pre-treatment of SJL mice
Three mg of MSCH, 200 µg of M. tb and 25 µg of M.b in 50 µl of PBS were
injected into the left hind footpads of 6-to-8-week old female SJL mice. To con-
trol the effect of mineral oil, some mice were injected with the same amount
of MSCH, M. tb and M. b in a water:mineral oil (1:1) emulsion (MSCH in
CFA). As a control of the effects of mycobacteria, some mice were pre-treat-
ed with only 200 µg of M. tb and 25 µg of M.b in 50 µl of PBS (without
MSCH). 
4.9.2 Induction of CR-EAE in the pre-treated mice 
In one experiment, two months after the pre-treatment, either 1.5 or 3 mg of
MSCH, plus 100 µg of M. tb and 12.5 µg of M. b in 25 µl of water-oil emul-
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sion (1:1) were injected into the right hind footpad (contralateral) of 10 and 5
mice, respectively. Immediately thereafter, the mice received an injection of
200 ng of PTX in 0.1 ml of PBS i.v.. As injection site controls, the second injec-
tion involving either 1.5 or 3 mg of MSCH was given into the left hind footpad
(homolateral) in two groups of 5 mice. The mice were evaluated daily and
disease severity was ranked as follows: 0, normal; 1, fur ruffling; 2, tail ato-
nia, slight hind limb paralysis; 3, severe hind limb paralysis; 4, complete hind
limb paralysis; 5, moribund. A clinical relapse was scored when a mouse devel-
oped a new neurological deficit (an increase in clinical severity of at least 1
grade) after a period of stabilization or improvement of its clinical score.
In another experiment, the same procedure was followed. However, the MSCH
and CFA emulsion was prepared with a much weaker sonicator. One group of
ten mice received 3 mg and another group of 9 mice received 1.5 mg of MSCH
in the second injection. The mice were checked four times daily and weighed
once daily at the same time point. Paralyzed mice were helped to food and
water. This experiment was terminated one month after the second injection. 
In the two control groups for monitoring the effects of mineral oil and mycobac-
teria, the second (contralateral) injection containing 1.5 mg of MSCH in CFA
was also given two months later. 
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4.10 Cell isolation, adoptive cell transfer and 
active EAE induction
Two months after the pre-treatment, the pre-treated mice (injected with MSCH
+ M. tb + M. b in PBS), mice treated with an unrelated antigen (MHH + M. tb
+ M. b), and mice injected with MSCH in CFA were killed by cervical disloca-
tion. Spleens and popliteal lymph nodes (pLN) that drain the pre-treatment
injection sites were removed under sterile conditions, and squeezed through a
sterilized steel mesh. Single cell suspensions were prepared in Eagle’s cell cul-
ture medium. Lymphocytes were isolated by density gradient centrifugation in
a LymphoprepTM solution (NYCOMED AS, Pharma Diagnostic Division, Oslo,
Norway), according to the manufacturer’s instructions. The purified lymphocytes
were counted, and immediately thereafter 10, 20 or 50 millions of either spleen
or lymph node cells were injected in 0.5 ml of Eagle’s solution into age-matched
mice through the tail vein. One week after the cell transfer, the recipient mice
were injected into the hind footpad with 3 mg of MSCH plus 100 µg of M. tb
and 12.5 µg of M. b in 25 µl of water-oil emulsion (1:1), followed by adminis-
tration of 200 ng of Pertussis toxin in 0.1 ml PBS through the tail vein immediately
thereafter. The conditions of the mice were assessed daily, and the disease sever-
ity was rated as follows: 0, normal; 1, fur ruffling; 2, tail atonia, slight hind limb
paralysis; 3, severe hind limb paralysis; 4, complete hind limb paralysis; 5,
complete paralysis in the four limbs; 6, moribund. The fatal outcome was also
rated as grade 6. A clinical relapse was scored when a mouse developed a new
neurological deficit (an increase in the clinical severity by at least one grade) after
a period of stabilization or improvement of its clinical score.
4.11 Induction of EAE in splenectomized and
lymphadenectomized mice
Splenectomy and lymphadenctomy were carried out on the pre-treated mice. Five
of the pre-treated mice, as well as 5 mice from each control group were splenec-
tomized, and another 5 were both splenectomized and lymphadenectomized. The
mice were anesthesized by ether inhalation. Following surgery the operation
wounds were closed and the mice were allowed to recover. One week after the
surgery, the operated mice were injected into the right hind footpad with 3 mg
of MSCH plus 100 µg of M. tb and 12.5 µg of M. b in 25 µl of water-oil emul-
sion (1:1). Thereafter 200 ng of pertussis toxin in 0.1 ml of PBS was administered
through the tail vain. The disease severity was scored daily as described above. 
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4.12 Histological examinations 
The mice were sacrificed and perfused with buffered 4% paraformaldehyde
through cardiac puncture. Brain tissue was subsequently immersed in the same
fixative overnight and embedded in paraffin. Sections were stained with hema-
toxylin and eosin and Luxol Fast blue (for myelin staining) and examined by
light microscopy. 
4.13 Gene subcloning 
Murine IL-1ß cDNA (1.9 kb) was provided by Dr. J.J. Huang, Sterling Research
Group (Malvern, PA, USA). Rat glyceraldehyde-3-phosphate dehydrogenase
(rGAPDH) cDNA was provided by Prof. R. Mäntyjärvi at the University of
Kuopio, Kuopio, Finland. Plasmids containing cDNA of murine IL-2 (mIL-
2) (0.93 bp), mIL-4 (590 bp), mIL-7 (492 bp), mIL-10 (500 bp), and mIFN-γ
(700 bp) were obtained from the American Type Culture Collection (ATCC)
(Rockville, MD, USA). These cDNA fragments were isolated by either elec-
trophoresis in a low melting point gel followed by agarase digestion or
QIAquick gel extraction kit according to the manufacturer’s instructions. For
subcloning, the plasmid containing a 1.9 kb IL-1ß cDNA was digested by Pst
I and a fragment of 103 bp was isolated, and subcloned into the PGEM3Z vec-
tor. The orientations of the subcloned plasmids were determined by either
enzyme digestion or direct sequencing. Similarly, a 333 bp fragment of mIL-
2 cDNA (obtained by digesting the original plamid with Pst I and Hind III)
was subcloned into PGEM3Z vector. A 1233 bp fragment of rGAPDH was
subcloned into PGEM 3Z vector at Pst I site. mIL-4, mIL-7, mIL-10 and mIFN-
γ were subcloned into PGEM 3Z vector. A 607 bp PCR product of murine
ICAM-5 (telencephalin) was subcloned into pGEM® vector, and the orienta-
tion was determined by sequencing. The plasmid constructs were transformed
into JM109 strain of E. coli, amplified in Luria broth culture medium and puri-
fied with the QIAGEN plasmid purification kit, according to the manufacturer’s
instructions. The DNA fragment inserts were excised by digestion with DNA
restriction enzymes, separated by electrophoresis in agarose gel and purified
with the QIAquick gel purification kit. The DNA fragments were used for DNA
probe preparation. 
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4.14 Total RNA extraction 
Total RNA extraction was carried out by a slightly modified protocol of
Chomczynski and Sacchi (269). Briefly, tissues or cell pellets were homoge-
nized in 4 M guanidinium thiocyanate and extracted in phenol: chloroform.
RNA contained in the supernatant after phenol:chloroform extraction was
precipitated in cold ethanol. 
4.15 Semi-quantitative RT-PCR
Thirty days after the contralateral injection (the second injection), the mice
were sacrificed by cervical dislocation. The spleens and popliteal lymph nodes
from both sides were immediately excised and frozen in liquid nitrogen. Total
RNA was isolated from the tissues by a modification of the method of
Chomczynski and Sacchi (269). Three micrograms of total RNA were reverse
transcribed with the SuperScriptTM choice system for cDNA synthesis (GIB-
CO BRL, Life Technologies Inc., Rockville, MD, USA) by using an oligo-dT
primer. The cDNA solution was further diluted 5 times in water, and 4 µl of it
was used for each PCR amplification. The primer sequences used in this study
are shown in Table 2. The PCR reactions were performed in 50 mM potassi-
um chloride, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 200 µM of each dATP,
dTTP, dGTP and dCTP, 1.25 units of AmpliTaq Gold DNA polymerase (Perkin
Elmer, Branchburg, NJ, USA) and 0.4 µM of each forward and reverse primer.
To prevent nonspecific amplification, a ”hot start” PCR protocol was applied:
94 ˚C incubation for 10 minutes at the beginning followed by three PCR cycles:
30 seconds at 94 ˚C; 1 minute at 60 ˚C; 2 minutes at 72 ˚C. At the end, the
reaction was held at 72 ˚C for 7 minutes. In order to keep the PCR reaction in
the exponential phase, eighteen and 25 circles of PCR amplification were used
for mouse GAPDH and other cytokines, respectively. The rat GAPDH cDNA
fragments were isolated with a QIAquick gel extraction kit and the PCR prod-
ucts of mouse cytokines and CAMs were purified with QIAquick PCR
purification kit. The sequences were confirmed by direct DNA sequencing
(100% match). The [a-32P] dCTP (NEN Life Science Products, Boston, MA.,
USA) labeled probes were made by random priming (DNA random primed
labeling kit, Boehringer Mannheim, Mannheim, Germany) to a specific activ-
ity of 0.9 - 2.1x 109 cpm/µg. The PCR products were transferred to nylon
membranes, hybridized with specific probes labeled with [a-32P] dCTP, and
quantified using the Fujifilm BAS-2500 phosphoimaging system. The amount
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Table 2. Primers for PCR reactions
GAPDH sense, 5’-TGA AGG TCG GTG TGA ACG GAT TTG GC-3’ 
antisense, 5’-CAT GTA GGC CAT GAG GTC CAC CAC-3’
IL-1ß sense, 5’-ATG GCA ACT GTT CCT GAA CTC AAC T-3’
antisense, 5’-CAG GAC AGG TAT AGA TTC TTT CCT TT-3’
IL-2 sense, 5’-GAC AGA AGG CTA TCC ATC TCC TCA GAA AGT CC-3’ 
antisense, 5’-GAC AGA AGG CTA TCC ATC TCC TCA GAA AGT CC-3’
IL-4 sense, 5’-ATG GGT CTC AAC CCC CAG CTA GT-3’ 
antisense, 5’-GCT CTT TAG GCT TTC CAG GAA GTC-3’
IL-7 sense, 5’-GCC TGT CAC ATC ATC TGA AGT GCC-3’
antisense, 5’-CAG GAG GCA TCC AGG AAC TTC TG-3’
IL-10 sense, 5’-ATG CAG GAC TTT AAG GGT TAC TTG GGT T-3’ 
antisense, 5’-ATT TCG GAG AGA GGT ACA AAC GAG GTT T-3’
IFN-g sense, 5’-TGC ATC TTG GCT TTG CAG CTC TTC CTC ATG GC-3’
antisense, 5’-TGG ACC TGT GGG TTG TTG ACC TCA AAC TTG GC-3’
ICAM-1 sense, 5’-CAA CTG GAA GCT GTT TGA GCT G-3’
antisense, 5’-TAG CTG GAA GAT CGA AAG TCC G-3’
ICAM-2 sense, 5’-TGC TGG AGC CTG TCT CTT CTT ATC-3’
antisense, 5’-TTC AGA GCT GTG CTG TTG AAC GTG-3’
VCAM-1 sense, 5’-CAA GGG TGA CCA GCT CAT GA-3’
antisense, 5’-TGT GCA GCC ACC TGA GAT CC-3’
LFA-1 sense, 5’-CCA CGA CAT AAC CCG CTA CAT CAT C-3’
antisense, 5’-TCC CCA CCA AAG TAA GAT CCG ATC-3’
CD44 sense, 5’-AAT TCC GAG GAT TCA TCC CA-3’
antisense, 5’-CGC TGC TGA CAT CGT CAT C-3’
ICAM-5 sense, 5’-GCG GTC GCG CTA GAA CCT TTC T-3’
antisense, 5’-GAA TGT GGA GGC ATG GCA AAG GTA-3’
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of cDNA used for each PCR reaction was normalized with GAPDH, i.e., the
relative value of each sample was expressed as a ratio between the numeral
value (from phosphoimaging analysis) of the target gene and GAPDH. 
4.16 In situ hybridization 
4.16.1 Preparation of RNA probes
The following components were sequentially added at RT: 4 µl of 2xTB buffer,
2 µl of 100 mM DTT, 1 µl of rRNasin, 4 µl of r(AGC)TP, 3 µl (1 µg) of lin-
earized DNA, 5 µl of [35α-S] rUTP, 1 µl of SP6 and T3 or T7 DNA dependent
RNA polymerase. The mixture was incubated for 1 hr. To remove the DNA
template, 1 µl of RQ1 RNase-free DNase was added and incubated for 15
min at 37˚C. Unincorporated nucleotides were removed by size chromatogra-
phy through prepacked G-50 Sephadex column. Labeled RNA probes were
precipitated in ethanol and suspended in 50 µl of RNA buffer X (10 mM Tris-
HCl, 1mM EDTA + 50 mM DTT). 
4.16.2 In situ hybridization of tissue specimens
Five µm sections of paraffin-embedded tissues were placed on silinase-coated
slides (super-frost plus), using DEPC-treated water. The sections were pre-
warmed at 60˚C for 2 hr and dewaxed in xylene (2x10) min, and then hydrated
in graded alcohol (absolute ethanol 2x5 min, 94% ethanol 1x3 min, 70% ethanol
1x3 min, 50% ethanol 1x3 min). The sections were rinsed in 1xPBS for 3 min,
denatured in 0.2 N HCl at RT for 20 min, washed in 2xSSC twice and heated
at 70˚C for 15 min. Following PBS washes the tissue was fixed in fresh 4%
paraformaldehyde (PFA) in 1xPBS for 12 min in a fumehood, washed again in
PBS and incubated with proteinase K (10 µg/ml in 50 mM Tris-HCl, 5 mM
EDTA at pH 8.0) at RT for 15 min. The tissue was washed once in 2xSSC and
once in PBS and fixed in 4% PFA for 10 min. Following washes in PBS twice,
the tissue was acetylated with 0.25% acetic anhydride in 0.1 M triethanolamine.
Following further washes in PBS, the tissue was dehydrated in graded ethanol
(50% ethanol: 3 min, 70% ethanol: 3 min, 94% ethanol: 3 min, 100% ethanol:
5 min) and dried in air. The tissue was incubated in the hybridization buffer
(50% deionized formamide, 0.3 M 0f NaCl, 10 mM of Tris. Cl, pH 8.0, 1 mM
of EDTA, 1XDenhardt’s solution, 10% of dextran sulphate, 50 mM of DTT, 0.5
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mg/ml of yeast tRNA) containing [35S] UTP labeled sense and anti-sense RNA
probes (4 million cpm/100 µl) at 50˚C for 4 hr. The probe was prepared with
riboprobe RNA labeling kit, according to the manufacturer’s instructions. The
slides were covered with parafilm and placed in a box containing the moisture
solution (2xSSC and 50% formamide). After the hybridization, the slides were
washed once in 2xSSC, 50% formamide containing 10 mM of DTT at 50˚C
for 30 min, once in 0.2xSSC containing 10 mM of DTT at 50˚C for 30 min and
once in NTE buffer (0.5 M of NaCl, 10 mM of Tris-HCl, 5 mM of EDTA at
pH 8.0). After the above washes, the tissues were incubated in an NTE buffer
containing RNase A (30 µg/ml) at 37˚C for 15 min. The tissue was further washed
once in 2xSSC and 50% formamide containing 10 mM of DTT at 50˚C for 15
min, then in 2xSSC at RT for 5 min. Following these washes, the slides were
dehydrated in graded ethanol: 50% ethanol 3min, 70% ethanol 3 min, 94%
ethanol 3 min, 100% ethanol 5min twice. The slides were dried in air when cov-
ered with a lid to protect them from dust. After this, melted Kodak NTB-2
emulsion was applied on the slides according to the procedure recommended
by the manufacturer. After drying in air in the dark room for at least 2 hr, the
slides were kept in a sealed light proof box and exposed at 4˚C for about two
weeks. The slides were developed with Kodak reagents, according to the man-
ufacturer’s instructions and counter stained with hematoxylin. After drying in
air, the slides were mounted with glass cover slids by use of permount, and exam-
ined under light microscope. 
4.17 Immunohistochemistry
Formalin-fixed, paraffin-embedded spleen tissue sections from normal mice
and normal human spleen were placed on polylysine-coated glass slides.
Sections were permeabilized with 0.3% Triton-X, blocked with 10% normal
goat serum and incubated overnight at +4˚C with the primary antibody in
dilutions 1:200-1:500, as appropriate. The three-step avidin-biotin
complex/horseradish peroxidase method (ABC, Vectastain, Vector Laboratories,
Burlingame, CA) was used with diaminobenzidine as the chromogen. Sections
were lightly counterstained with Meyer’s Hemalum. Adjacent sections incu-
bated with normal rabbit serum in similar dilutions underwent the same staining
protocol and were examined as controls. Light microscopy was performed with
Leitz Laborlux D (Leitz, Wetzlar, Germany) microscope equipped with Nikon
Coolpix 995 (Nikon, Japan) digital camera.
MATERIALS AND METHODS 
Jinghui jang  30.10.2003  13:56  Sivu 45
46
4.18 Flow cytometry
4.18.1 Direct isolation of splenic dendritic cells and macrophages
Spleens from adult male ICR mice were cut into small pieces and incubated
at 37˚C in RPMI 1640 supplemented with 0.5% FCS, 0.02 mg/ml DNase I
(Roche Diagnostics GmbH, Mannheim, Germany) and 0.1 mg/ml of collage-
nase (Sigma-Aldrich) that was free of tryptic activity. The cell suspension was
filtered through a fine steel mesh and the cells were collected by centrifuga-
tion at 200g. Splenic dendritic cells were enriched by MACS with anti-CD11c
magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) using posi-
tive selection columns. CD11c- cells were used to isolate CD11b+ splenic
macrophages by MACS with anti-CD11b magnetic beads. 
4.18.2 FACS analysis
ICAM-5 expression was measured by immunofluorescence. Enriched CD11c+
dendritic cells and CD11b+ macrophages were stained with rabbit anti-human
ICAM-5 polyclonal antibody first. After washing in PBS twice, the cells were
stained with goat anti-rabbit monoclonal antibody conjugated with FITC. After
washing, the cells were stained with APC-conjugated with hamster anti-mouse
CD11c monoclonal antibody (clone HL3, BD Biosciences Pharmingen). An
aliquot of cells received an APC conjugated irrelevant Ab of the same iso-
type. As a negative control for the FITC labeling, one aliquot of cells did not
receive the primary anti-ICAM-5 but all the other antibodies. Surface fluo-
rescence was assayed by flow cytometry. The eluted cells after the two-round
positive selection, which contained T and B cells were stained for ICAM-5
expression as mentioned. After washing, the cells were stained with R-PE-con-
jugated rat anti-mouse CD3 (clone 17A2, BD Biosciences Pharmingen) and
PerCP-CY5.5-conjugated rat anti-mouse CD19 (clone 1D3, BD Biosciences
Pharmingen). Triple color FACS analysis was performed for the surface fluo-
rescence thereafter. 
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5 RESULTS
5.1 Stimulation of murine splenic cells by SFV-A7 and LPS
5.1.1 mRNA expression of IL-1ß and IL-2 induced by LPS and SFV-A7
Cytokines play a pivotal role in both infections and autoimmune diseases. Thus,
one could assume that an altered immune response with a co-pathogen infec-
tion might be associated with an altered cytokine production. In the first study
the methodology for the quantification of cytokine mRNA expression in CR-
EAE was established. For this, the effects of LPS and SFV-A7 on cytokine
mRNA expression in mouse splenic cells was characterized. LPS at 10 ng/ml
and SFV-A7 at 5 m.o.i. was added to the cell culture and IL-1ß and IL-2 mRNA
expression was studied by Northern blot hybridization and phosphoimaging
analysis. It was found that 10 ng/ml of LPS induced substantial IL-1ß expres-
sion. However, IL-2 mRNA expression was not increased by this treatment.
SFV-A7 induced neither significant IL-1ß nor IL-2 mRNA expression. 
5.1.2 Combined effects of LPS and SFV-A7 on IL-1ß and IL-2
mRNA expression
To study whether or not a combined treatment of SFV-A7 and LPS could result
in an enhanced cytokine mRNA expression, SFV-A7 (m.o.i. of 5) and 10 ng/ml
of LPS were added to the splenic cell culture at the same time. The mRNA
expression of both IL-1ß and IL-2 was increased at 3 and 6 h but not at 1 and
12 h, as compared with LPS or SFV-A7 treatment alone. Further study demon-
strated that an addition of SFV-A7 3 h before LPS enhanced IL-1 mRNA
expression as compared with a 3 h culture with LPS alone. However, when
SFV-A7 was added 3 hours later, the IL-1ß mRNA expression was actually
reduced, as compared with a 6 hours culture with LPS alone. On the other hand,
this treatment did not affect IL-2 mRNA expression. 
5.2 Induction of CR-EAE
5.2.1 Effects of paraffin oil in the pre-treatment
Paraffin oil is usually used for the preparation of the antigen emulsion for the
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induction of EAE in mice. To determine if EAE can still be induced without
paraffin oil (IFA), MSCH, M. tb and M. b in PBS were injected into the hind
footpad of the mice. This treatment proved to be inefficient in inducing EAE:
only 24% of the mice in one group developed slight and transient hind limb
paralysis, whilst the majority remained normal. In another experiment, all the
mice failed to show any clinical sign of illness after the pre-treatment. These
results demonstrate that at least paraffin oil is needed for the induction of
clinical EAE. 
5.2.2 CR-EAE induced in the pre-treated mice after the contralateral
injection
Although the sub-optimal pre-treatment failed to induce EAE in SJL mice, it
may produce memory responses which in turn may affect the conventional
EAE induction. To study the nature of EAE induced in the pre-treated mice,
we immunized the mice with a standard acute EAE induction treatment two
months after the pre-treatment (Fig. 1). In experiment I, the neuroantigen emul-
sion was prepared with a stronger sonicator, in contrast to a weaker sonicator
used in experiment II. It was found that, in experiment I, all the 10 mice receiv-
ing 1.5 mg of MSCH in the second (contralateral) injection demonstrated
complete paralysis within 7 days after the injection, as compared with usual-
ly 9 days in acute EAE induced with a single injection regimen. Two mice died
during the acute attack. One mouse recovered from severe paralysis to mild
paralysis (from grade 5 to grade 2). This mouse had one relapse but failed to
recover from it and died at grade 4 (30 days after the second injection). All
the rest of the mice had a slow recovery (that lasted between 20 to 30 days)
before they stabilized at grade 2. In this group of mice, we observed 5 rather
clear relapses within the next 11 months. Similarly, the 5 mice which received
3 mg of MSCH in CFA in the contralateral (right) hind footpad also had an
early onset of disease (within 7 days), which became chronic thereafter. All
the 5 mice demonstrated clear-cut relapses (often with an increase of two
grades). However, 4 mice died of the first relapse within one month. Only
one mouse showed persistent paralysis until it was sacrificed after 15 weeks. 
In experiment II where the neuroantigen emulsion was prepared with a weak-
er sonicator, the majority of mice survived the acute disease attack and
developed either a chronic and/or relapsing EAE. We observed 6 clear-cut
relapses in this group (see reference 76 and paper II). The weights of the mice
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were measured once a day. It was found that the change in weight paralleled
the change in the clinical status of the mice: the mice gained weight when they
were recovering and lost weight when they had relapses. 
To control the effect of paraffin oil, a group of 6 mice were pre-treated with 3
mg of MSCH in CFA, followed by a second (contralateral injection) two months
later. It was observed that some mice developed severe EAE with an earlier
disease onset (7 days after the second injection) and died. Some recovered
completely and remained normal thereafer. No relapses were recorded. In the
control group for the effect of mycobacteria, none of the mice showed any
signs of illness at any point during the experiment. 
5.2.3 Disease induction by a single injection regimen
It has been reported that CR-EAE could be induced in SJL mice by a single
injection of neuroantigen in CFA. To test this, naive SJL/J mice were inject-
ed with different doses of MSCH in CFA. All the mice developed a monophasic
acute EAE. The disease onset was about 12 days after the injection. All the
mice survived the acute disease attack and recovered quickly and remained
normal thereafter. If pertussis toxin was injected i.v. after the injection of MSCH
in CFA, all mice died of EAE. 
5.2.4 Effects of injection sites on the induction of EAE
CR-EAE developed in the pre-treated SJL mice after the contralateral injec-
tion of MSCH in CFA as described above. Interestingly, if a homolateral
injection (i.e. the first and the second injections into the same footpad) of MSCH
in CFA was given to the pre-treated mice, all the mice died of a severe acute
disease attack. 
5.3 Effect of splenectomy and lymphadenectomy
To analyze the effect of memory cells on the induction of CR-EAE, we con-
ducted splenectomy and lymphadenectomy on the pre-treated mice. Five mice
from each group were splenectomized two months after the pre-treatment.
These splenectomized mice received a contralateral injection of MSCH in CFA
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one week after the operation. It was found that splenectomy per se substantial-
ly abolished the development of CR-EAE. Two mice died of an acute attack.
Two mice recovered slowly and one remained normal. Not a single relapse was
recorded during a follow-up of 41 days. When both splenectomy and lym-
phadenectomy were performed, not only the CR-EAE was abolished but also
the disease was ameliorated dramatically: four out of five mice developed a typ-
ical acute EAE with a quick recovery. Only one mouse died after 3 weeks; one
mouse made a slow recovery, but no relapse was recorded during the 41-day fol-
low-up period. Thus, it can be concluded that the immune cells harbored in the
spleen after the pre-treatment play a pivotal role in the development of CR-EAE.
5.4 Effect of adoptive cell transfer
Next it was asked whether an adoptive transfer of putative memory lympho-
cytes from the pre-treated mice would affect the development of EAE induced
by active immunization. Lymphocytes were isolated from either the spleen or
the local draining popliteal lymph nodes of the suboptimally pre-treated mice
two months after the pretreatment. Different amounts of cells were transferred
to naive syngeneic recipients one week before active immunization. It was
found that the transfer of pLN cells exacerbated the disease: all the 10 mice
died of an acute attack and their average maximum disease index was signif-
icantly higher than in mice that received a spleen cell transfer (Student’s t-test,
p<0.02). On the contrary, a transfer of splenic lymphocytes delayed the onset
of the disease to an average 16.3 days after immunization, as compared to an
average of 10.7 days after the pLN transfer (p<0.01). Furthermore, as many as
50% of mice survived compared to no survivors after the pLN cell transfer. 
Most interestingly, CR-EAE developed only in the group of mice with spleen
cell transfer. Five clear-cut relapses were recorded in five of the seven surviv-
ing mice. This suggested that the spleen cells could harbor memory cells that
affect the development of CR-EAE. 
5.5 Histological examination
Brains from mice that survived the 11 months’ follow-up in the first experi-
ment of CR-EAE showed an inflammatory cell infiltrate in the ventricular areas,
especially around the blood vessels and adjacent tissue. There was a more
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pronounced mononuclear cell infiltration in mice with severe paralysis than
in mice with mild paralysis. It is of interest to note that the inflammatory cell
infiltrate in our CR-EAE model is highly disseminated, and without an obvi-
ous focus, which is atypical of EAE in SJL mice. 
In mice with CR-EAE, extensive demyelination was observed with Luxol
fast blue staining. 
5.6 Cytokine mRNA expression 
Because cytokines play a pivotal role in inflammation and autoimmune respons-
es, we asked whether a specific expression pattern of cytokines would be
associated with the disease course in CR-EAE. At the termination of the exper-
iment (30 days after the contralateral injection) cytokine mRNA expression
in the pLN and spleen was studied in the two groups of mice with either a
severe paralysis (n=5) or complete remission (n=6) by semi-quantitative RT-
PCR. In order to keep the PCR reaction in the exponential phase the yield of
the PCR reaction was kept under 50 ng. 
The tested cytokines included IL-1β, IL-2, IL-4, IL-7, IL-10 and IFN-γ. All
of them were found to be expressed at considerable levels in both groups of
mice. Surprisingly, the expression levels of the cytokine mRNAs tested between
the groups of mice with either relapse or remission was not found to be sig-
nificantly different. Interestingly, when the cytokine mRNA expression was
compared between the LNs and the spleens within the group of mice with
remission, the expressions of IL-2, IFN-γ and IL-10 (but not of IL-1β, IL-4
or IL-7) were found to be significantly higher in the LNs than in the spleens
(p<0.01 for IL-2 and IFN-γ; p<0.05 for IL-10; Student’s t-test). However, in
the group of mice with relapse, although the mRNA expression of IL-2 and
IFN-γ was slightly higher in the LNs than in the spleens in this group, no sig-
nificant differences were found between levels of any cytokine mRNAs tested.
Unlike the mice with remission, the mice with relapse showed actually a high-
er expression of IL-10 mRNA in the spleens than in the LNs. However, this
difference was not statistically significant. 
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5.7 mRNA expression of cellular adhesion molecules (CAMs)
The cellular adhesion molecules (CAMs) are believed to play a role in the traf-
fic of lymphocytes. The immigration and emigration of encephalitogenic T cells
to and from the CNS is a hallmark of CR-EAE. Thus, we studied the mRNA
expression of ICAM-1 and 2, VCAM-1, LFA-1 and CD44 in the two groups
of mice with either relapse or remission by semi-quantitative RT-PCR. All the
tested CAMs were found to be expressed in all the samples. The mRNA expres-
sions of CAMs in LNs or spleens between the two groups of mice with either
relapse or remission was not significantly different. However, when the mRNA
expression was compared between the LNs and the spleens in the group of mice
with remission, a significantly higher expression was found for VCAM-1, LFA-
1 and CD44 in the spleen than in the LNs (p<0.01 for VCAM-1 and LFA-1;
p<0.05 for CD44; Student’s t test ). In contrast, no such significant difference
was found in the group of mice with relapse. Likewise, mRNA expression of
ICAM-5 between mice with either relapse or remission was not significantly
different. Interestingly, it was found that ICAM-5 mRNA expression was sig-
nificantly higher in the spleens than in the pLNs of mice with disease remission,
but not of mice with relapse. 
5.8 ICAM-5 mRNA expression studied by in situ
hybridization
ICAM-5 (telencephalin) is a recently characterized integral membrane glyco-
protein of the Ig superfamily. It has been reported that ICAM-5 was expressed
exclusively in telencephalic neurons. In order to see whether ICAM-5 was also
expressed in the peripheral lymphoid organs, ICAM-5 mRNA expression
was studied in the spleen in the naive SJL mice by in situ hybridization. It
was found that ICAM-5 mRNA was expressed in the red pulp area of the spleen. 
5.9 Immunohistochemistry staining of ICAM-5 protein 
in the spleen 
To determine whether ICAM-5 was expressed at the protein level in the sec-
ondary lymphoid organs, we performed immunohistochemistry staining of both
mouse and human spleens. It was found that the red pulp (r) area of mouse
spleen stained positive for ICAM-5 intensely, as compared to the rather scat-
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tered positive staining in the white pulp (w) area surrounding the central artery.
The cells staining positive for ICAM-5 in the white pulp appeared to be non-
lymphocytoid cells with an abundant cytoplasm. Likewise, the human spleen
tissue demonstrated a similar scattered staining pattern in the area of white
pulp (w) adjacent to a central artery. The ICAM-5 positive cells did not mor-
phologically correspond to monocytoid lymphocytes, which are the
predominant cell type found in the B-cell -rich marginal zone of white pulp
adjucent to the T-cell -rich periarterial lymphatic sheath (PALS). Similarly to
the mouse spleen, more cells in the red pulp of human spleen stained positive
for ICAM-5. 
5.10 Flow cytometry demonstration of ICAM-5 on 
dendritic cells
In order to determine the phenotype of cells that expressed ICAM-5 in the
mouse spleen, we conducted multi-color-labeling FACS analysis of the enriched
CD11c+ dendritic cells and CD11b+ macrophages as well as of T cells and B
cells collected after positive selection. It was found that 58% of CD11c+ den-
dritic cells stained positive for ICAM-5. A similar percentage of CD11b+
macrophages was also found to stain positively for ICAM-5 (data not shown).
However, only about 37% of CD19+ B cells and about 10% of CD3+ T cells
stained positive for ICAM-5. Interestingly, it appeared that two distinct groups
of dendritic cells expressed ICAM-5, one group staining brighter than the oth-
er. The CD11b+ macrophages stained to the same extent as the CD11c+
dendritic cells that stained less bright.
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6 DISCUSSION
6.1 IL-1ß and IL-2 mRNA expression in murine splenic cells
It has been reported that predisposing C57BL/J mice to SFV-A7 virus facili-
tated the induction of EAE (270). It has also been found that an infection of
BALB/c and SJL/J mice with SFV-A7 virus could either inhibit or facilitate
the development of EAE, depending on whether the virus was injected before
or after the EAE induction (271). The mechanisms underlying these phenom-
ena remain unknown. EAE is a CD4+ T cell mediated, delayed type
hypersensitivity in which cytokines play a central role (77). Therefore, it was
speculated that an altered cytokine production due to the interaction between
SFV-A7 and mycobacterial components, the major factor in CFA, might be
responsible for the altered autoimmune response. Thus, it was tested whether
a concomitant stimulation by SFV-A7 and LPS, a complex glycolipid and the
major component of the outer membrane of Gram-negative bacteria (272),
would result in an altered cytokine expression. In this respect IL-2 and IL-1β
are probably important, since IL-2 supports T cell development, and its pro-
duction is influenced by IL-1, a major pro-inflammatory cytokine with
pleiotropic properties (273, 274). In addition, the methods for splenic cell trans-
fer as well as for the quantification of cytokine mRNAs were established for
use throughout this work. Infection with the Semliki Forest virus mutant SFV-
A7 alone did not activate IL-1ß and IL-2 mRNA expression by mouse splenic
cells. However, SFV-A7 enhanced the effect of LPS on the expression of these
two cytokines. The enhancing effects were even more pronounced if the SFV-
A7 was added 3 h before LPS addition, while adding the virus 3 h after the
addition of LPS inhibited the effect of LPS. The results demonstrate that a con-
comitant stimulation of murine splenic cells with viral and bacterial components
can result in an altered cytokine production. It has been speculated that an
infection with a co-pathogen might play a role in autoimmunity (275). Since
cytokines play a major role in autoimmune diseases, it can be assumed that a
concomitant infection could affect disease pathogenesis via an altered cytokine
production. 
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6.2 CR-EAE as an animal model for human MS
As one of the most thoroughly studied animal models for human autoim-
mune diseases, EAE has served well in elucidating the cellular and molecular
mechanisms of autoimmunity (77, 171, 276). However, the often monopha-
sic disease course in acute EAE is only remotely related to human MS (277).
Because CR-EAE resembles the unique clinical features of MS, various pro-
tocols for the induction of CR-EAE have been described (74, 75, 278).
Nevertheless, convincing relapsing EAE has always proved difficult to pro-
duce. As a result, the CR-EAE models described so far are either with mild or
rare relapses. For these reasons, the establishment of more appropriate ani-
mal models for human MS has recently been advocated (3). With a modified
protocol, a CR-EAE model which is characterized by a high percentage of sur-
vival, frequent and clear-cut relapses was established. This CR-EAE model
has proven to be highly reproducible (in three different laboratories) and should
facilitate the study of the mechanisms of chronicity and relapse of human
demyelinating diseases. 
6.3 Biased immune memory precipitates the chronicity 
of the autoimmunity
As it has been reported and confirmed in this study, a single immunization reg-
imen involving neuroantigen and adjuvants usually induced a monophasic acute
EAE (277). Brown et al induced relapsing EAE with two identical injections
with a one-week interval (75), indicating the relevance of immune memory
to subsequently developing chronic autoimmunity. The results reported in this
thesis have demonstrated that a biased immune memory caused by a sub-
optimal immunization is critical in altering an otherwise acute EAE into a
chronic disease. In contrast, a full scale assault of acute EAE tends to cause
resistance to later EAE inductions, if the mice survive (279). This phenome-
non is of interest, given the fact that the development of human MS has been
believed to be preceded by infections in late adolescence (21, 22, 26). It is pro-
posed that the pre-treatment in our protocol for inducing CR-EAE is reminiscent
of a late childhood infection which precipitates MS later in the adulthood. Thus,
a subclinical neurotropic infection in adolescence could cause a biased immune
memory towards certain self neuroantigens. This pathogenic immune memo-
ry could interact with immune responses to subsequent infections in the
adulthood, and result in the development of MS. 
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Although the co-stimulation and/or ”danger” theories (126, 127) could
explain how the autoimmune response can be initiated, they fail to explain
why infections are frequent but autoimmune diseases are relatively rare. They
also fail to explain the chronicity of virtually all autoimmune diseases. It can
be postulated that the development of autoimmune diseases is a slow process
of the break-down of the immune homeostasis and tolerance which can not
be attributed to a single infection. Rather, the interactions of the immune
memories after various infections that occurred during different periods of
human life may contribute more to the loss of immune homeostasis. Indeed,
these results have demonstrated that the memory cells that developed after
a sub-optimal treatment were able to convert an otherwise actively induced
acute EAE into a CR-EAE in the naive recipient mice. However, the mech-
anism underlying the development of chronic autoimmunity in our model
remains unknown. Likewise, the impact of the memory from different infec-
tions on the development of chronic autoimmune diseases has not been
adequately studied. 
6.4 Differential immune response within the secondary
immune compartments might determine the outcome of
autoimmune disease progression
It has been optimistically believed that the two antagonistic patterns of
cytokines, i.e., Th1- and Th2-type response (167), could determine the over-
all immune response in autoimmune demyelinating diseases (171). However,
recent data indicates that the Th1/Th2 dogma is oversimplified. In EAE, it
has been reported that myelin basic protein-specific Th2 cells actually cause
EAE in immunodeficient hosts rather than protect the host from the disease
(182). Likewise, it has been shown that IFN-γ, a Th1 cytokine, could sup-
press EAE and IFN-γ knockout mice had a more severe EAE (184-187).
However, the treatment of MS patients with IFN-γ actually exacerbated the
disease (188). In our study, we observed that both Th1 and Th2 cytokine
mRNAs were expressed in mice with either relapse or remission. Interestingly,
we found that a differential expression of certain cytokines (IL-2, IFN-γ, IL-
10) between spleens and lymph nodes was associated with disease remission
in CR-EAE. The mechanism is unknown. However, it can be speculated that
cytokines function in a finely coordinated nonlinear network in which a slight
quantitative change of certain cytokines may have a dramatic systemic effect
(165). The results indicate that the relative amounts of cytokines produced at
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different locations (i.e. LN versus spleen) in the peripheral lymphoid organs
may be important in the immune regulation and the development of CR-EAE. 
CAMs are molecules that regulate the trafficking of lymphocytes (198). The
selected expression of CAMs in certain immune compartments not only tar-
gets the effector cells to sites of antigenic or microbial invasion, but also directs
lymphocyte subsets to the specialized microenvironments that control their dif-
ferentiation and regulate their survival (196). It has been reported that the
expression levels of LFA-1 and CD44 on infiltrating mononuclear cells and on
some resident cells in MS and EAE brains were increased (193, 213, 276). It
has also been found that upregulation of ICAM-1 and VCAM-1 in CNS coin-
cided with the immigration of CD4+ lymphocytes, while downregulation
coincided with their emigration (239). It was found that disease remission in
CR-EAE was associated with a relatively increased mRNA expression of
VCAM-1, LFA-1 and CD44 in the spleen and a decreased mRNA expression
in pLNs. 
Parallel to the above findings, we also found that the memory cells from the
spleen were more involved in the development of CR-EAE. Immune response
in one compartment might be synergistic or antagonistic to the immune response
initiated in another compartment. In this regard, the deviated expression of
cytokines and CAMs in LNs versus spleens might favor the development of
functionally different T-cell subsets in these two immune compartments. Indeed,
it has been reported that the spleen, but not LN, is a major source of suppres-
sor T cell activity (280-283) and is needed for the suppression of EAE (284,
285). It can be speculated that an elevated expression of IL-2 and IFN-γ in LNs
may enhance the activation-induced apoptosis of the autoimmune T cells and
facilitate disease recovery accordingly. Conversely, the downregulated expres-
sion of IL-10 as well as the upregulated expression of VCAM-1, LFA-1 and
CD44 in the spleen may favour the development of regulatory T cells which
suppress the activity of encephalitogenic T cells. Alternatively, it can be assumed
that the increased expression of LFA-1, CD44 and VCAM-1 in the spleen
may help to trap the encephalitogenic T cells in the spleen, and thus prevent
them from emigrating into the CNS. 
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6.5 Expression of ICAM-5 outside the CNS and 
role in CR-EAE
In this study, ICAM-5 was found to be strongly expressed on CD11c+ DCs and
its mRNA expression was elevated in the spleen of mice with disease remis-
sion, suggesting that ICAM-5 might be such a molecule that suppresses the
autoimmune response. 
The antigen presenting cells (APCs) express many accessory molecules that
interact with receptors on T cells to enhance adhesion and signalling (co-stim-
ulation). These molecules include LFA-3/CD58, ICAM-1/CD54 and
B7-2/CD86 (256). The direction of T cell development largely depends on
which co-stimulatory molecules are expressed by the APCs. Microbial prod-
ucts may activate DCs through binding to Toll-like receptors (257, 258), and
thus result in the up-regulation of MHC class II and costimulatory molecules
(CD80/CD86), and the development of pathogen-specific T cells. However,
the so called ”tolerogenic” DCs that play a pivotal role in immune homeosta-
sis may express totally different co-suppressor molecules (286). Self-antigen
presentation to T cells by the tolerogenic APCs may lead to either a deletion
of autoimmune T cells or the development of regulatory T cells (Tr) (287).
Indeed, it has been reported that the myelin basic protein (MBP)-pulsed thymic
DCs can prevent the development of EAE when injected intravenously into
adoptive hosts (288). Thus, expression of ICAM-5 on DCs may facilitate the
development of regulatory T cells that suppress the disease progression in
CR-EAE. 
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SUMMARY AND CONCLUSIONS
The hallmark of autoimmune diseases is the chronic tissue damage caused by
a persisting or recurrent autoimmune response. Thus, to understand the patho-
genesis of autoimmune diseases, it is important to know not only how the
autoimmune response is initiated but also why it becomes chronic. Increasing
evidence has pointed to the critical involvement of peripheral immune regu-
lation in the development and control of chronic autoimmune demyelinating
diseases in the CNS. In the present work, the disease evolution of chronic
relapsing experimental autoimmune encephalomyelitis (CR-EAE) in SJL mice
was investigated. Attention was directed to studying the expression of vari-
ous immune parameters in the secondary lymphoid organs of mice with either
relapsing or remitting course of the disease. 
It was observed that the acute disease course of conventional EAE could be
converted into CR-EAE by a pre-treatment which itself was sub-optimal for
the induction of EAE. Apparently, the pre-existing immune status resulting
from the pre-treatment influenced the subsequent immune activity of a stan-
dard acute EAE induction and resulted in a break-down of immune homeostasis
in the peripheral immune organs. Further studies using splenectomy, lym-
phadenectomy as well as adoptive cell transfer indicated that it was the splenic
memory T cells developed after the pre-treatment that interacted with a sec-
ondary immunization and were responsible for the development of the chronic
disease course. 
The expression of several immune parameters in the peripheral lymphoid
organs, namely, lymph nodes and spleens of mice with either disease relapse
or remission were studied. No significant difference in the expression of
cytokines (IL-2, IFN-γ, IL-10) or adhesion molecules (VCAM-1, LFA-1, CD44)
was found between the mice having either disease relapse or remission.
Interestingly, however, a higher mRNA expression of cytokines IL-2, IFN-γ,
IL-10 and adhesion molecules VCAM-1, LFA-1, CD44 in the spleens than in
the lymph nodes was observed in mice with disease remission but not relapse.
These results indicated that an increased expression of certain cytokines as
well as adhesion molecules in the spleen might be beneficial to the control of
autoimmune response. 
Finally, we studied the expression of ICAM-5, an interesting novel adhesion
molecule, in the spleens of humans and naive mice as well as in mice with CR-
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EAE. For the first time, we identified that ICAM-5 was expressed in the red
pulp area of human and mouse spleens. Flow cytometry analysis revealed
that ICAM-5 was expressed on the surface of dendritic cells, macrophages and
a small percentage of B cells. Furthermore, we observed that a higher expres-
sion of ICAM-5 in the spleen than in the lymph nodes was associated with
disease remission in CR-EAE. 
In the present study, a novel mouse model for human MS was established with
a modified protocol. Because this new model resembles human MS closely, it
can be used for studying the pathogenesis of MS as well as for testing thera-
peutic approaches. The role of the spleen in suppressing the autoimmune
response and influencing the relapsing-remitting nature of EAE was particu-
larly intriguing. The observation of a differential expression of cytokines as
well as CAMs in different peripheral lymphoid organs may also help in the
design of therapies by manipulating the expression of various immune param-
eters in the peripheral lymphoid organs. 
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